Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Receivables: 2019-2025

Historic Change in Receivables for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $4.3 million.

  • C4 Therapeutics' Change in Receivables fell 52.68% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 138.60%. This contributed to the annual value of -$8.7 million for FY2024, which is 184.22% down from last year.
  • Latest data reveals that C4 Therapeutics reported Change in Receivables of $4.3 million as of Q3 2025, which was up 174.50% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Change in Receivables ranged from a high of $11.3 million in Q4 2023 and a low of -$12.4 million during Q2 2024.
  • In the last 3 years, C4 Therapeutics' Change in Receivables had a median value of $500,000 in 2023 and averaged $460,909.
  • Per our database at Business Quant, C4 Therapeutics' Change in Receivables soared by 75,433.33% in 2023 and then slumped by 2,586.20% in 2024.
  • C4 Therapeutics' Change in Receivables (Quarterly) stood at $871,000 in 2021, then plummeted by 101.72% to -$15,000 in 2022, then soared by 75,433.33% to $11.3 million in 2023, then tumbled by 164.06% to -$7.2 million in 2024, then slumped by 52.68% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, -$5.8 million for Q2 2025, and $4.9 million during Q1 2025.